The high specificity and sensitivity of the CRISPR diagnostics, e.g. SHERLOCK, can detect the presence of the pathogen genome and report out the result accurately through the CRISPR-Cas system. It provides genome targeting based results and is superior to any serological based rapid test kits (RTKs). This project aims to improve the CRISPR diagnostic platform with an amplification-free approach, to enable a novel and robust RTK for SARS-COV2 detection.